Deciphera Pharmaceuticals Inc.

47.00-0.2300-0.49%Vol 411.12K1Y Perf 8.48%
Apr 16th, 2021 16:00 DELAYED
BID47.00 ASK47.02
Open47.40 Previous Close47.23
Pre-Market- After-Market-
 - -  - -%
Target Price
73.71 
Analyst Rating
Strong Buy 1.40
Potential %
56.83 
Finscreener Ranking
★★★★+     57.00
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     54.61
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     63.59
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap2.71B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
26.16 
Earnings Date
4th May 2021

Today's Price Range

45.0247.54

52W Range

39.4268.40

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
7.28%
1 Month
6.92%
3 Months
-6.13%
6 Months
-20.22%
1 Year
8.48%
3 Years
97.65%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
DCPH47.00-0.2300-0.49
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
8.10
8.30
0.05
0.06
-22 579.40
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
99.50
-1 198.90
-1 189.80
-
-
RevenueValueIndustryS&P 500US Markets
42.03M
0.73
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.16-1.105.17
Q03 2020-1.32-1.1314.39
Q02 2020-1.34-1.2010.45
Q01 2020-1.28-1.36-6.25
Q04 2019-1.13-1.31-15.93
Q03 2019-1.19-1.28-7.56
Q02 2019-1.06-0.5647.17
Q01 2019-0.79-1.25-58.23
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.096.03Positive
6/2021 QR-0.9615.79Positive
12/2021 FY-4.273.17Positive
12/2022 FY-2.6310.24Positive
Next Report Date4th May 2021
Estimated EPS Next Report-1.09
Estimates Count5
EPS Growth Next 5 Years %21.00
Volume Overview
Volume411.12K
Shares Outstanding57.63M
Trades Count6.23K
Dollar Volume19.33M
Avg. Volume434.10K
Avg. Weekly Volume322.21K
Avg. Monthly Volume362.72K
Avg. Quarterly Volume443.64K

Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) stock closed at 47 per share at the end of the most recent trading day (a -0.49% change compared to the prior day closing price) with a volume of 414.52K shares and market capitalization of 2.71B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 350 people. Deciphera Pharmaceuticals Inc. CEO is Steven L. Hoerter.

The one-year performance of Deciphera Pharmaceuticals Inc. stock is 8.48%, while year-to-date (YTD) performance is -17.64%. DCPH stock has a five-year performance of %. Its 52-week range is between 39.42 and 68.4, which gives DCPH stock a 52-week price range ratio of 26.16%

Deciphera Pharmaceuticals Inc. currently has a PE ratio of -9.30, a price-to-book (PB) ratio of 4.71, a price-to-sale (PS) ratio of 60.40, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.37%, a ROC of -46.13% and a ROE of -46.81%. The company’s profit margin is -%, its EBITDA margin is -1 189.80%, and its revenue ttm is $42.03 Million , which makes it $0.73 revenue per share.

Of the last four earnings reports from Deciphera Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.09 for the next earnings report. Deciphera Pharmaceuticals Inc.’s next earnings report date is 04th May 2021.

The consensus rating of Wall Street analysts for Deciphera Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $73.71, which is +56.83% compared to the current price. The earnings rating for Deciphera Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Deciphera Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Deciphera Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.65, ATR14 : 2.56, CCI20 : 121.82, Chaikin Money Flow : 0.13, MACD : -0.66, Money Flow Index : 59.48, ROC : 13.17, RSI : 49.88, STOCH (14,3) : 93.35, STOCH RSI : 0.96, UO : 61.19, Williams %R : -6.65), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Deciphera Pharmaceuticals Inc. in the last 12-months were: Daniel Flynn (Option Excercise at a value of $262 765), Daniel Flynn (Sold 508 shares of value $24 826 ), James Bristol (Option Excercise at a value of $219 192), James Bristol (Sold 92 323 shares of value $4 846 785 ), Matthew L. Sherman (Option Excercise at a value of $99 985), Matthew L. Sherman (Sold 132 shares of value $6 451 ), Michael Taylor (Option Excercise at a value of $1 083 157), Michael Taylor (Sold 573 099 shares of value $31 455 514 ), Patricia L. Allen (Option Excercise at a value of $617 520), Patricia L. Allen (Sold 24 000 shares of value $1 382 897 ), Steven L. Hoerter (Option Excercise at a value of $51 181), Thomas P. Kelly (Option Excercise at a value of $45 360), Thomas P. Kelly (Sold 24 524 shares of value $1 253 940 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (80.00 %)
9 (81.82 %)
10 (90.91 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (20.00 %)
2 (18.18 %)
1 (9.09 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.36
Strong Buy
1.18

Deciphera Pharmaceuticals Inc.

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

CEO: Steven L. Hoerter

Telephone: +1 781 209-6400

Address: 200 Smith Street, Waltham 02451, MA, US

Number of employees: 350

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

52%48%

Bearish Bullish

48%52%

News

Stocktwits